Introduction: The clinicopathologic features and prognostic predictors of radiological part‐solid lung adenocarcinomas were unclear. Methods: We retrospectively compared the clinicopathologic features and survival times of part‐solid tumors with those of pure ground glass nodules (pGGNs) and pure solid tumors treated with surgery at Fudan University Shanghai Cancer Center and evaluated the prognostic implications of consolidation‐to‐tumor ratio (CTR), solid component size, and tumor size for part‐solid lung adenocarcinomas. Results: A total of 911 patients and 988 pulmonary nodules (including 329 part‐solid nodules [PSNs], 501 pGGNs, and 158 pure solid nodules) were analyzed. More female patients (p = 0.015) and nonsmokers (p = 0.003) were seen with PSNs than with pure solid nodules. The prevalence of lymphatic metastasis was lower in patients with PSNs than in those with pure solid tumors (2.2% versus 27% [p < 0.001]). The 5‐year lung cancer–specific (LCS) recurrence‐free survival and LCS overall survival of patients with PSNs were worse than those of patients with pGGNs (p < 0.001 and p = .042, respectively) but better than those of patients with pure solid tumors ([p < 0.001 and p < 0.0001, respectively]). CTR (OR = 12.90; 95% confidence interval [CI]: 1.85–90.04), solid component size (OR = 1.45; 95% CI: 1.28–1.64), and tumor size (OR = 1.23; 95% CI: 1.15–1.31) could predict pathologic invasive adenocarcinoma for patients with PSNs. None of them could predict the prognosis. Patients receiving sublobar resection had prognoses comparable to those of patients receiving lobectomy (p = .178 for 5‐year LCS recurrence‐free survival and p = .319 for 5‐year LCS overall survival). The prognostic differences between patients with systemic lymph node dissection and those without systemic lymph node dissection were statistically insignificant. Conclusions: Part‐solid lung adenocarcinoma showed clinicopathologic features different from those of pure solid tumor. CTR, solid component size, and tumor size could not predict the prognosis. Part‐solid lung adenocarcinomas define one special clinical subtype.

中文翻译：

---

表现为放射学部分实性结节的肺腺癌定义了一种特殊的临床亚型

介绍：放射学部分实性肺腺癌的临床病理特征和预后预测因素尚不清楚。方法：我们回顾性比较复旦大学上海癌症中心手术治疗的部分实体瘤与纯磨玻璃结节（pGGNs）和纯实体瘤的临床病理特征和生存时间，并评估实变对肿瘤的预后意义。部分实性肺腺癌的比率（CTR）、实性成分大小和肿瘤大小。结果：共分析了 911 名患者和 988 个肺结节（包括 329 个部分实性结节 [PSNs]、501 个 pGGNs 和 158 个纯实性结节）。与纯实性结节相比，使用 PSN 的女性患者 (p = 0.015) 和不吸烟者 (p = 0.003) 多。PSN 患者的淋巴转移发生率低于纯实体瘤患者（2.2% 对 27% [p < 0.001]）。PSNs 患者的 5 年肺癌特异性 (LCS) 无复发生存率和 LCS 总生存率低于 pGGNs 患者（分别为 p < 0.001 和 p = .042），但优于 pGGNs 患者。纯实体瘤（[分别为 p < 0.001 和 p < 0.0001]）。CTR（OR = 12.90；95% 置信区间 [CI]：1.85–90.04）、实体成分大小（OR = 1.45；95% CI：1.28–1.64）和肿瘤大小（OR = 1.23；95% CI：1.15– 1.31) 可以预测 PSN 患者的病理浸润性腺癌。他们都无法预测预后。接受亚肺叶切除术的患者的预后与接受肺叶切除术的患者相当（p = . 5 年 LCS 无复发生存率为 178，5 年 LCS 总生存率 p = .319）。全身淋巴结清扫术患者与非全身淋巴结清扫术患者的预后差异无统计学意义。结论：部分实性肺腺癌的临床病理特征与纯实体瘤不同。CTR、实体成分大小和肿瘤大小不能预测预后。部分实性肺腺癌定义了一种特殊的临床亚型。部分实性肺腺癌表现出与纯实体瘤不同的临床病理特征。CTR、实体成分大小和肿瘤大小不能预测预后。部分实性肺腺癌定义了一种特殊的临床亚型。部分实性肺腺癌表现出与纯实体瘤不同的临床病理特征。CTR、实体成分大小和肿瘤大小不能预测预后。部分实性肺腺癌定义了一种特殊的临床亚型。